UNSPSC 51312503: Dimethindene or dimetindene

This classification denotes a histamine h1 antagonist, antipruritic, and anti-allergic agent with the molecular formula C20H24N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 661FH77Z3P, chemically known as 1h-indene-2-ethanamine, n,n-dimethyl-3-(1-(2-pyridinyl)ethyl)- (9ci) but generally known as dimetindene, which bears US NIH Compound Identifier 21855. European Medicines Agency schedules Dimetindene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07179MIG.

UNSPSC 51312503 Dimethindene or dimetindene (Commodity) covers pharmaceutical products, but the recent state and local opportunities tagged under this code show little direct alignment with dimethindene itself — instead they reflect procurement of naloxone, generic multi-source pharmaceuticals, and direct-to-manufacturer prescription programs. State and local health departments, benefits administrators, and cooperative purchasing alliances are the primary issuing bodies, soliciting pharmaceutical products through RFPs, RFQs, and IFBs to support community health initiatives, employee and retiree health plans, and statewide pharmacy benefit programs. The solicitations emphasize compliance with FDA and Drug Supply Chain Security Act requirements, competitive pricing models, and quarterly or ongoing supply arrangements. Vendors must demonstrate current Good Manufacturing Practices certification, maintain adequate insurance coverage including commercial general liability and professional liability, and support electronic data interchange and wholesaler chargeback systems.

Recent activity spans Florida, Texas, Minnesota, and Oregon through a mix of county health departments and state multi-agency cooperative purchasing vehicles. Seminole County, Florida posted IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries by July 26, 2023 (note: date discrepancy in source). The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to explore direct-to-manufacturer prescription contracting models outside traditional pharmacy benefit manager arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) posted an RFP for generic multi-source pharmaceuticals and over-the-counter products in January 2026 with a March 26, 2026 response deadline, distributing awards across three authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson) with a July 1, 2026 effective date. Pricing competitiveness weighted at 75 percent and two-year initial terms are standard across these opportunities.